Neoadjuvant Immune Checkpoint Inhibitor Therapy in Resectable Non-Small Cell Lung Cancer
Cet article analyse les données cliniques et précliniques évaluant l'intérêt des inhibiteurs de points de contrôle immunitaire en traitement néoadjuvant d'un cancer du poumon non à petites cellules résécable
Only a minority of lung cancers are resectable at diagnosis, and many of these will eventually relapse. Adjuvant chemotherapy in this setting has a modest survival advantage, and there is significant need for new approaches to improve cure rates. Checkpoint inhibitor immunotherapy has transformed the prognosis for advanced lung cancer, and is increasingly being used in the neoadjuvant setting alone, or in combination with cytotoxic chemotherapy. While this has demonstrated convincing improvements in event-free survival and pathologic response, questions remain over optimal duration of therapy, predictive and prognostic biomarkers, response assessment and combination with other modalities. In addition, these results must be considered in the context of recent positive studies of adjuvant immunotherapy. Here, we summarise preclinical context and clinical trials in this space, discuss areas of controversy and pitfalls, and consider future challenges.
Lung Cancer 2023